[1] GERAGHTY J. Adenomatous polyposis coli andtranslational medicine[J]. Lancet,1996,348(9025):422.[2] MEI T,KIM A,VONG L B,et al. Encapsulationof tissue plasminogen activator in pH-sensitive selfassembledantioxidant nanoparticles for ischemicstroke treatment - Synergistic effect of thrombolysisand antioxidant[J/OL]. Biomaterials,2019,215:119209[2019-11-10]. https://doi.org/10.1016/j.biomaterials.2019.05.020.[3] DIRKS M,NIESSEN L W,VAN WIJNGAARDENJ D,et al. Promoting thrombolysis in acute ischemicstroke[J]. Stroke,2011,42(5):1325-1330.[4] SMITH M,REDDY U,ROBBA C. Acute ischaemicstroke:challenges for the intensivist[J]. Intens CareMed,2019,45(9):1177-1189.[5] JIAN Z,LIU R,ZHU X,et al. The involvementand therapy target of immune cells after ischemicstroke[J/OL]. Front Immunol,2019,10:2167[2019-11-10]. https://doi.org/10.3389/fimmu.2019.02167.[6] FLURI F,SCHUHMANN M K,KLEINSCHNITZC. Animal models of ischemic stroke and theirapplication in clinical research[J]. Drug Des DevelTher,2015,9:3445-3454.[7] FODDIS M,WINEK K,BENTELE K,et al.An exploratory investigation of brain collateralcirculation plasticity after cerebral ischemia in twoexperimental C57BL/6 mouse models[J]. J CerebrBlood F Met,2020,40(2):276-287.[8] WELLS A J,VINK R,HELPS S C,et al. Elevatedintracranial pressure and cerebral edema followingpermanent MCA occlusion in an ovine model[J/OL].PLoS One,2015,10(6):e0130512[2019-11-10].https://doi.org/10.1371/journal.pone.0130512.[9] LEE J H,JONES C F,OKON E B,et al. A novelporcine model of traumatic thoracic spinal cordinjury[J]. J Neurotrauma,2013,30(3):142-159.[10] CHAUHAN A,MOSER H,MCCULLOUGH LD. Sex differences in ischaemic stroke:potentialcellular mechanisms[J]. Clin Sci(Lond),2017,131(7):533-552.[11] CARRASQUILLA G D,FRUMENTO P,BERGLUND A,et al. Postmenopausal hormonetherapy and risk of stroke:a pooled analysis of datafrom population-based cohort studies[J/OL]. PLoSMed,2017,14(11):e1002445[2019-11-10]. https://doi.org/10.1371/journal.pmed.1002445.[12] GRIEMERT E V,RECARTE PELZ K,ENGELHARD K,et al. PAI-1 but not PAI-2 genedeficiency attenuates ischemic brain injury afterexperimental stroke[J]. Transl Stroke Res,2019,10(4):372-380.[13] MCCABE C,ARROJA M M,REID E,et al. Animalmodels of ischaemic stroke and characterisation ofthe ischaemic penumbra[J]. Neuropharmacology,2018,134(Pt B):169-177.[14] ALLRED R P,ADKINS D L,WOODLEE M T,etal. The vermicelli handling test:a simple quantitativemeasure of dexterous forepaw function in rats[J]. JNeurosci Methods,2008,170(2):229-244.[15] CORDOVA C A,JACKSON D,LANGDON K D,etal. Impaired executive function following ischemicstroke in the rat medial prefrontal cortex[J]. BehavBrain Res,2014,258:106-111.[16] CRAMER S C,KOROSHETZ W J,FINKLESTEINS P. The case for modality-specific outcomemeasures in clinical trials of stroke recoverypromotingagents[J]. Stroke,2007,38(4):1393-1395.[17] BUSHNELL C,BETTGER J P,COCKROFTK M,et al. Chronic stroke outcome measuresfor motor function intervention trials:expertpanel recommendations[J]. Circ Cardiovasc QualOutcomes,2015,8(6 Suppl 3):S163-S169.[18] HILL M D. Stroke:the dashed hopes ofneuroprotection[J]. Lancet Neurol,2007,6(1):2-3.[19] ELKINS J,VELTKAMP R,MONTANER J,et al.Safety and efficacy of natalizumab in patients withacute ischaemic stroke(ACTION):a randomised,placebo-controlled,double-blind phase 2 trial[J].Lancet Neurol,2017,16(3):217-226.[20] AVERT Trial Collaboration group. Efficacy andsafety of very early mobilisation within 24 h ofstroke onset(AVERT):a randomised controlledtrial[J]. Lancet,2015,386(9988):46-55.[21] HILL M D,MARTIN R H,MIKULIS D,etal. Safety and efficacy of NA-1 in patients withiatrogenic stroke after endovascular aneurysm repair (ENACT):a phase 2,randomised,double-blind,placebo-controlled trial[J]. Lancet Neurol,2012,11(11):942-950.[22] XU L J,OUYANG Y B,XIONG X,et al. Poststroketreatment with miR-181 antagomir reducesinjury and improves long-term behavioral recoveryin mice after focal cerebral ischemia[J]. Exp Neurol,2015,264:1-7.[23] KIM T,MEHTA S L,KAIMAL B,et al. Poststrokeinduction of alpha-synuclein mediates ischemic braindamage[J]. J Neurosci,2016,36(26):7055-7065.[24] YIN K J,OLSEN K,HAMBLIN M,et al. Vascularendothelial cell-specific microRNA-15a inhibitsangiogenesis in hindlimb ischemia[J]. J Biol Chem,2012,287(32):27055-27064.[25] CHEVILLEY A,LESEPT F,LENOIR S,et al.Impacts of tissue-type plasminogen activator(tPA)on neuronal survival[J/OL]. Front Cell Neurosci,2015,9:415[2019-11-10]. https://doi.org/10.3389/fncel.2015.00415.